SYDNEY, Australia, June 23 Pharmaxis(ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australianpharmaceutical executive Will Delaat to its board of directors.
Mr Delaat has 35 years experience in the global pharmaceutical industry,most recently as the managing director of the Australian subsidiary of Merck &Co., a position he held from 1997 until his recent retirement.
During his career Mr Delaat has held executive positions in both Europeand Australia for Merck and AstraZeneca. Mr Delaat is experienced in sales andmarketing and has been responsible for international product launches andcommercialisation of respiratory products.
Mr Delaat also serves the pharmaceutical industry in importantrepresentative roles. He is chairman of the Australian pharmaceuticalindustry's peak body, Medicines Australia, and is chairman of thePharmaceuticals Industry Council.
''Will Delaat is one of Australia's pharmaceutical industry leaders'' saidPharmaxis Chairman, Denis Hanley. ''The Pharmaxis board will benefit from hisinvaluable skills and experience.''
In accepting the board director position Mr Delaat said: ''Pharmaxis holdsenormous promise and I look forward to being part of its effort to bringinnovative medicines to patients world-wide."
For information on all Pharmaxis Board members, go tohttp://tinyurl.com/3s4g2n .
The statements contained in this media release that are not purelyhistorical are forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended. Forward-looking statements inthis media release include statements regarding our expectations, beliefs,hopes, goals, intentions, initiatives or strategies, including statementsregarding the potential for Aridol and/or Bronchitol. Allforward-looking statements included in this media release are based uponinformationavailable to us as of the date hereof, and we assume no obligation to updateany such forward-looking statement as a result of new information, futureevents or otherwise. We can not guarantee that any product candidate willreceive FDA or other regulatory approval or that we will seek any suchapproval. Factors that could cause or contribute to such differences include,but are not limited to, factors discussed in the "Risk Factors and OtherUncertainties" section of our Form 20-F lodged with the U.S. Securities andExchange Commission.CONTACT: Alan Robertson Chief Executive Officer Tel: +61-2-9454-7200 Email: firstname.lastname@example.org RELEASED THROUGH: Australia: Virginia Nicholls Tel: +61-417-610-824 Email: email@example.com United States: Brandon Lewis, Trout Group Tel: +1-646-378-2915 Email: firstname.lastname@example.org
SOURCE Pharmaxis Ltd